Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 03-0491827 ( ...

Vanda Pharmaceuticals, Inc. (NASDAQ:VNDA) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Mihael Polymeropoulos - President, Chairman and CEO Kevin Moran - CFO Tim Williams - Senior Vice President and General Counsel Conference Call Participants Operator Thank you for standing by. My name is Hermine, and I will be your conference operator today. At this time, I would like to welcome everyone to Q1 2024 Vanda Pharmaceuticals, Inc. Earnings Conference Call. All lines have been pla ...

Exhibit 99.1 Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results WASHINGTON – May 8, 2024 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2024. "We are very proud of our accomplishments in the first quarter of 2024, which were achieved with a small but efficient organization that is enthusiastic to continue developing and commercializing treatments for people who need them," said Mihael H. Polymeropoul ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 03-0491827 (State or other jurisdiction of incorporation or organizat ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2023 Earnings Conference Call February 7, 2024 4:30 PM ET Company Participants Kevin Moran - Chief Financial Officer Mihael Polymeropoulos - President, Chief Executive Officer & Chairman Tim Williams - General Counsel Conference Call Participants Andrew Tsai - Jefferies Operator Good afternoon. My name is Jeannie and I will be your conference operator today. At this time, I would like to welcome everyone to the Q4 2023 Vanda Pharmaceuticals Inc. Earnings Conferenc ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 03-04918 ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Kevin Moran - SVP, CFO and Treasurer Dr. Mihael Polymeropoulos - President, CEO and Chairman Tim Williams - General Counsel Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today. At this time, I would like to welcome everyone to the Third Quarter 2023 Vanda Pharmaceuticals, Inc. Earnings Conference Call. [Operator Instr ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 03-0491827 (S ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2023 Earnings Call July 27, 2023 4:30 PM ET Company Participants Mihael H. Polymeropoulos - President, Chief Executive Officer and Chairman of the Board Kevin Moran - Senior Vice President, Chief Financial Officer and Treasurer Tim Williams - General Counsel Conference Call Participants Andrew Tsai - Jefferies Operator Good afternoon. My name is Audra, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q2 2023 Vanda ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q1 2023 Earnings Conference Call May 3, 2023 4:30 AM ET Company Participants Kevin Moran - CFO Mihael Polymeropoulos - President, CEO and Chairman Timothy Williams - General Counsel Conference Call Participants Operator Good afternoon. My name is David and I’ll be your conference operator today. At this time, I’d like to welcome everyone to the Q1 2023 Vanda Pharmaceuticals Inc. Earnings Conference Call. Today’s conference is being recorded. All lines have been place ...